Dyne Therapeutics, Inc. Common Stock

Dyne Therapeutics trades with a surprising 16.84% short interest despite sitting nowhere near its 52-week high, suggesting lingering skepticism about the biotech's fundamentals. The stock's RSI of 59.6 sits in neutral territory—neither oversold nor approaching overbought conditions—while the absence of a meaningful P/E ratio reflects typical pre-profitability pharma dynamics. For a $3.1B market-cap company, the elevated short ratio combined with room to its peak creates an interesting tension: either shorts are betting on clinical setbacks ahead, or there's genuine skepticism about pipeline execution. The technical setup lacks extreme pressure in either direction, offering relatively balanced risk-reward positioning without obvious squeeze dynamics.